Short Interest in Autonomix Medical, Inc. (NASDAQ:AMIX) Decreases By 22.2%

Autonomix Medical, Inc. (NASDAQ:AMIX) saw a significant decrease in short interest in August. As of August 15th, there was short interest totaling 330,700 shares, a decrease of 22.2% from the July 31st total of 425,300 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 8.4% of the company’s shares are short sold. Approximately 8.4% of the company’s shares are short sold. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

AMIX has been the topic of several research analyst reports. Zacks Research cut Autonomix Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 28th. Wall Street Zen upgraded Autonomix Medical to a “sell” rating in a report on Saturday, July 26th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Autonomix Medical currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Autonomix Medical Stock Up 1.7%

Autonomix Medical stock opened at $1.19 on Wednesday. The business has a fifty day moving average of $1.29 and a two-hundred day moving average of $1.65. The firm has a market cap of $7.04 million, a P/E ratio of -0.21 and a beta of -2.97. Autonomix Medical has a twelve month low of $0.96 and a twelve month high of $21.49.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.09). Equities analysts expect that Autonomix Medical will post -10 earnings per share for the current year.

Institutional Trading of Autonomix Medical

An institutional investor recently bought a new position in Autonomix Medical stock. Citadel Advisors LLC acquired a new stake in shares of Autonomix Medical, Inc. (NASDAQ:AMIX) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 47,884 shares of the company’s stock, valued at approximately $180,000. Citadel Advisors LLC owned about 4.16% of Autonomix Medical at the end of the most recent quarter. Institutional investors and hedge funds own 10.78% of the company’s stock.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.